Table 1.
Variable | Type 1 diabetes patients [n = 100] | Age and sex matched controls [n = 62] | p value |
---|---|---|---|
Age [years] | 42.2 ± 13.4 | 44.1 ± 16.8 | 0.4443 |
Duration of diabetes [years] | 17.3 ± 10.1 | – | – |
Chromogranin A [ng/mL]a | 61.64 ± 55.27 | 48.03 ± 19.99 | 0.0348 |
Chromogranin B [ng/mL] | 89.39 ± 34.23 | 107.38 ± 59.77 | 0.0241 |
HbA1C [%] | 8.0 ± 1.7 | – | – |
HbA1C [mmol/mol] | 64.0 ± 18.6 | – | – |
White blood cell count [109/L] | 6.91 ± 1.77 | 7.08 ± 1.95 | 0.5894 |
Red blood cell count [1012/L] | 4.88 ± 0.51 | 5.04 ± 0.56 | 0.0739 |
eGFR [mLmin−1(1.73m2)−1] | 100.79 ± 18.65 | 100.26 ± 16.10 | 0.8483 |
Body mass index (BMI) [kg/m2] | 25.6 ± 5.0 | 25.9 ± 5.3 | 0.7505 |
Sex (Female / Male) | 50: 50 | 31: 31 | 1.0000 |
Hypertension | 47 | 17 | 0.0140 |
Thyroid disease | 31 | 4 | 0.0002 |
Gastroesophageal reflux disease | 14 | 7 | 0.8104 |
Antacid therapy | 6 | 5 | 0.7499 |
Values are expressed as mean ± standard deviation, unit of anamnestic data is the number of observations
eGFR Estimated glomerular filtration rate, HbA1C Glycated hemoglobin
aExcluding the measurement of study subjects, who had any condition leading to chromogranin A elevation [3, 4, 7]. Remaining number of observations was 91 and 56, respectively